Deltex Medical Group plc (AIM: DEMG), the global leader in Oesophageal Doppler Monitoring (“ODM”), is pleased to announce that Andy Mears, the Company’s Chief Executive Officer, will be presenting at an investor evening…
Leading the way in Goal-Directed Haemodynamic Therapy
Clinically proven to Reduce Avoidable Complications
Reducing overall risk of complication by half, and even more dramatic reduction in specific complications such as acute kidney injury, points to the significant potential of ODM technology if adopted as standard of care
Professor Jose María Calvo Vecino, Chief of Anaesthesia and Intensive Care, University of Salamanca, Spain, lead researcher in FEDORA 420 patient RCT, pub March 2018
Sign up to stay in touch
Our e-newsletter is a great way to keep up with the latest news and information about Deltex Medical.
- Clinical Library & Education
- Innovation Health & Wealth Report
Innovation Health and Wealth: Accelerating Adoption and Diffusion in the NHS, was published in December 2011 and identified Oesophageal Doppler Monitoring (ODM) as one of six High Impact Innovations recommended for widespread use across the NHS. The aim; to improve productivity, quality and patient outcomes.